...drives ARRY up nearly 10% in AH trading.
SNTA blows up nearly 50% on the strength of a handful of BC patients.
Makes me wonder what EXEL is capable of in the wake of more strong data.
GLTA that made some dough today...
EXEL's turn is coming no doubt
I cannot argue the point, given the "go-nowhere"for long periods of time circumstances that surround EXEL, but it begs the question..."How's that work, Al...???"
If GS controls the stock action with a paltry 2.9 M shares, what do the other institutional holders have to say in the matter. FMR, Wellington, Capital Research, T Rowe Price, Meditor, Vanguard, Blackrock, State St, and Barclays Global all own more than GS...in fact, in the aggregate they own over 120M shares...or roughly 40X the Goldman Sachs holding. Surely they carry some stroke...
Are you suggesting that all these institutions are working in collusion to keep EXEL under $5/share??
How's that work, Al...???